Outcome after cavo-tricuspid isthmus ablation in patients with recurrent atrial fibrillation and drug-related typical atrial flutter.
This study evaluates the long-term clinical outcome of 56 consecutive patients affected by atrial fibrillation and drug-related typical atrial flutter who underwent cavo-tricuspid isthmus radiofrequency ablation. Symptomatic arrhythmic events recurred after ablation in 64% of the patients during follow-up of 19 +/- 9 months. Even in those who had recurrences, there was a substantial reduction in the incidence of episodes, quality of life was improved, and hospitalizations decreased.
Bottoni
Nicola
N
Unità Operativa di Cardiologia Interventistica, Dipartimento di Cardiologia, Azienda Ospedaliera S. Maria Nuova, V. Risorgimento 80, Reggio Emilia, Italy. bottoni.nicola@asmn.re.it
Donateo
Paolo
P
Quartieri
Fabio
F
Tomasi
Corrado
C
Oddone
Daniele
D
Lolli
Gino
G
Menozzi
Carlo
C
Brignole
Michele
M
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001282:Atrial Flutter / Q000139:chemically induced* / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010359:Patient Readmission / Q000706:statistics & numerical data; D011183:Postoperative Complications / Q000209:etiology*; D011788:Quality of Life; D012008:Recurrence; D014261:Tricuspid Valve / Q000601:surgery*; D014683:Vena Cava, Superior / Q000601:surgery*
D000889:Anti-Arrhythmia Agents